Skip to main content

Table 3.

Clinical trials targeting interleukin (IL)-29

Intervention Indication Clinical stage Sponsor
PEG-rIL-29 Hepatitis C Phase I NCT00565539
Phase II NCT01001754
ZymoGenetics
PEG-rIL-29 Hepatitis C Phase III NCT01718158
Phase III NCT01598090
Phase III NCT01754974
Phase III NCT01866930
Phase III NCT01616524
Bristol-Myers Squibb
PEG-rIL-29 Hepatitis D Phase II NCT02765802 Eiger BioPharmaceuticals

Data source: clinicaltrials.gov.